135 related articles for article (PubMed ID: 36190964)
1. Computational Modeling of TP63-TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics.
Ozdemir ES; Gomes MM; Fischer JM
Mol Cancer Ther; 2022 Dec; 21(12):1846-1856. PubMed ID: 36190964
[TBL] [Abstract][Full Text] [Related]
2. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
3. Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings.
Mitani Y; Li J; Weber RS; Lippman SL; Flores ER; Caulin C; El-Naggar AK
Am J Pathol; 2011 Jul; 179(1):391-9. PubMed ID: 21703418
[TBL] [Abstract][Full Text] [Related]
4. p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and DeltaN isoforms.
Okuyama T; Kurata S; Tomimori Y; Fukunishi N; Sato S; Osada M; Tsukinoki K; Jin HF; Yamashita A; Ito M; Kobayashi S; Hata RI; Ikawa Y; Katoh I
Oncogene; 2008 Jan; 27(3):308-17. PubMed ID: 17637751
[TBL] [Abstract][Full Text] [Related]
5. Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal.
DeCoste RC; Carter MD; Pasternak S; Fleming KE; Gaston D; Legge A; Ly TY; Walsh NM
Hum Pathol; 2021 Nov; 117():31-41. PubMed ID: 34391748
[TBL] [Abstract][Full Text] [Related]
6. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.
Candi E; Agostini M; Melino G; Bernassola F
Hum Mutat; 2014 Jun; 35(6):702-14. PubMed ID: 24488880
[TBL] [Abstract][Full Text] [Related]
7. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.
Sethi I; Romano RA; Gluck C; Smalley K; Vojtesek B; Buck MJ; Sinha S
BMC Genomics; 2015 Aug; 16():584. PubMed ID: 26251276
[TBL] [Abstract][Full Text] [Related]
8. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
[TBL] [Abstract][Full Text] [Related]
9. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
[TBL] [Abstract][Full Text] [Related]
10. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells.
Petitjean A; Cavard C; Shi H; Tribollet V; Hainaut P; Caron de Fromentel C
Oncogene; 2005 Jan; 24(3):512-9. PubMed ID: 15543231
[TBL] [Abstract][Full Text] [Related]
11. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.
Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C
Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390
[TBL] [Abstract][Full Text] [Related]
12. Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma.
Herfs M; Hubert P; Suarez-Carmona M; Reschner A; Saussez S; Berx G; Savagner P; Boniver J; Delvenne P
Am J Pathol; 2010 Apr; 176(4):1941-9. PubMed ID: 20150431
[TBL] [Abstract][Full Text] [Related]
13. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
14. TP63 isoform expression is linked with distinct clinical outcomes in cancer.
Bankhead A; McMaster T; Wang Y; Boonstra PS; Palmbos PL
EBioMedicine; 2020 Jan; 51():102561. PubMed ID: 31927310
[TBL] [Abstract][Full Text] [Related]
15. TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.
Costanzo A; Pediconi N; Narcisi A; Guerrieri F; Belloni L; Fausti F; Botti E; Levrero M
FEBS Lett; 2014 Aug; 588(16):2590-9. PubMed ID: 24983500
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells.
Parsons JK; Saria EA; Nakayama M; Vessella RL; Sawyers CL; Isaacs WB; Faith DA; Bova GS; Samathanam CA; Mitchell R; De Marzo AM
Prostate; 2009 Apr; 69(5):559-69. PubMed ID: 19142959
[TBL] [Abstract][Full Text] [Related]
17. TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.
Monti P; Ghiorzo P; Menichini P; Foggetti G; Queirolo P; Izzotti A; Fronza G
Oncol Rep; 2017 Oct; 38(4):1985-1994. PubMed ID: 28849221
[TBL] [Abstract][Full Text] [Related]
18. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
Chen YK; Hsue SS; Lin LM
Int J Oral Maxillofac Surg; 2004 Jul; 33(5):493-7. PubMed ID: 15183414
[TBL] [Abstract][Full Text] [Related]
19. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.
Abbas HA; Bui NHB; Rajapakshe K; Wong J; Gunaratne P; Tsai KY; Coarfa C; Flores ER
Cancer Res; 2018 Jan; 78(2):451-462. PubMed ID: 29180475
[TBL] [Abstract][Full Text] [Related]
20. Caspase-1 is a novel target of p63 in tumor suppression.
Celardo I; Grespi F; Antonov A; Bernassola F; Garabadgiu AV; Melino G; Amelio I
Cell Death Dis; 2013 May; 4(5):e645. PubMed ID: 23703390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
